BioCentury
ARTICLE | Emerging Company Profile

Singling out ovarian cancer

GamaMabs' antibody activates immune cells against AMHR2-positive ovarian tumors

June 22, 2015 7:00 AM UTC

GamaMabs Pharma S.A. is developing a first-in-class mAb that has the potential to treat chemotherapy-resistant subtypes of ovarian cancer by activating phagocytosis in tumor-infiltrating immune cells and tethering them to tumor cells expressing a cancer-specific antigen.

GamaMabs' 3C23K is a humanized mAb against anti-Mullerian hormone receptor type II (AMHR2), a protein that is overexpressed on 50-70% of epithelial ovarian tumors and on nearly 100% of mucinous and granulosa ovarian cancers, which do not respond to chemotherapy...